These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 35652336)

  • 1. Phase II study of alisertib as a single agent for treating recurrent or progressive atypical teratoid/rhabdoid tumor.
    Upadhyaya SA; Campagne O; Billups CA; Orr BA; Onar-Thomas A; Tatevossian RG; Mostafavi R; Myers JR; Vinitsky A; Moreira DC; Lindsay HB; Kilburn L; Baxter P; Smith A; Crawford JR; Partap S; Bendel AE; Aguilera DG; Nichols KE; Rampersaud E; Ellison DW; Klimo P; Patay Z; Robinson GW; Broniscer A; Stewart CF; Wetmore C; Gajjar A
    Neuro Oncol; 2023 Feb; 25(2):386-397. PubMed ID: 35652336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Alisertib is active as single agent in recurrent atypical teratoid rhabdoid tumors in 4 children.
    Wetmore C; Boyett J; Li S; Lin T; Bendel A; Gajjar A; Orr BA
    Neuro Oncol; 2015 Jun; 17(6):882-8. PubMed ID: 25688119
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigational Aurora A kinase inhibitor alisertib (MLN8237) as an enteric-coated tablet formulation in non-hematologic malignancies: phase 1 dose-escalation study.
    Falchook G; Kurzrock R; Gouw L; Hong D; McGregor KA; Zhou X; Shi H; Fingert H; Sharma S
    Invest New Drugs; 2014 Dec; 32(6):1181-7. PubMed ID: 24879333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.
    O'Connor OA; Özcan M; Jacobsen ED; Roncero JM; Trotman J; Demeter J; Masszi T; Pereira J; Ramchandren R; Beaven A; Caballero D; Horwitz SM; Lennard A; Turgut M; Hamerschlak N; d'Amore FA; Foss F; Kim WS; Leonard JP; Zinzani PL; Chiattone CS; Hsi ED; Trümper L; Liu H; Sheldon-Waniga E; Ullmann CD; Venkatakrishnan K; Leonard EJ; Shustov AR;
    J Clin Oncol; 2019 Mar; 37(8):613-623. PubMed ID: 30707661
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase 1 study of the investigational Aurora A kinase inhibitor alisertib (MLN8237) in East Asian cancer patients: pharmacokinetics and recommended phase 2 dose.
    Venkatakrishnan K; Kim TM; Lin CC; Thye LS; Chng WJ; Ma B; Chen MH; Zhou X; Liu H; Kelly V; Kim WS
    Invest New Drugs; 2015 Aug; 33(4):942-53. PubMed ID: 26084989
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An open-label, single-arm, phase 2 study of the Aurora kinase A inhibitor alisertib in patients with advanced urothelial cancer.
    Necchi A; Lo Vullo S; Mariani L; Raggi D; Giannatempo P; Calareso G; Togliardi E; Crippa F; Di Genova N; Perrone F; Colecchia M; Paolini B; Pelosi G; Nicolai N; Procopio G; Salvioni R; De Braud FG
    Invest New Drugs; 2016 Apr; 34(2):236-42. PubMed ID: 26873642
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase II Study of Alisertib in Children with Recurrent/Refractory Solid Tumors or Leukemia: Children's Oncology Group Phase I and Pilot Consortium (ADVL0921).
    Mossé YP; Fox E; Teachey DT; Reid JM; Safgren SL; Carol H; Lock RB; Houghton PJ; Smith MA; Hall D; Barkauskas DA; Krailo M; Voss SD; Berg SL; Blaney SM; Weigel BJ
    Clin Cancer Res; 2019 Jun; 25(11):3229-3238. PubMed ID: 30777875
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of alisertib, a selective Aurora A kinase inhibitor, in relapsed and refractory aggressive B- and T-cell non-Hodgkin lymphomas.
    Friedberg JW; Mahadevan D; Cebula E; Persky D; Lossos I; Agarwal AB; Jung J; Burack R; Zhou X; Leonard EJ; Fingert H; Danaee H; Bernstein SH
    J Clin Oncol; 2014 Jan; 32(1):44-50. PubMed ID: 24043741
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mass balance, routes of excretion, and pharmacokinetics of investigational oral [
    Zhou X; Pusalkar S; Chowdhury SK; Searle S; Li Y; Ullmann CD; Venkatakrishnan K
    Invest New Drugs; 2019 Aug; 37(4):666-673. PubMed ID: 30397836
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of alisertib, an investigational aurora a kinase inhibitor on the QTc interval in patients with advanced malignancies.
    Zhou X; Nemunaitis J; Pant S; Bauer TM; Patel M; Sarantopoulos J; Craig Lockhart A; Goodman D; Huebner D; Mould DR; Venkatakrishnan K
    Invest New Drugs; 2018 Apr; 36(2):240-247. PubMed ID: 28819760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Relative bioavailability of a prototype oral solution of the Aurora A kinase inhibitor alisertib (MLN8237) in patients with advanced solid tumors.
    Falchook GS; Venkatakrishnan K; Sarantopoulos J; Kurzrock R; Mita AC; Fu S; Mita MM; Zhou X; Jung JA; Ullmann CD; Milch C; Rosen LS
    Int J Clin Pharmacol Ther; 2015 Jul; 53(7):563-72. PubMed ID: 26073352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia.
    Fathi AT; Wander SA; Blonquist TM; Brunner AM; Amrein PC; Supko J; Hermance NM; Manning AL; Sadrzadeh H; Ballen KK; Attar EC; Graubert TA; Hobbs G; Joseph C; Perry AM; Burke M; Silver R; Foster J; Bergeron M; Ramos AY; Som TT; Fishman KM; McGregor KL; Connolly C; Neuberg DS; Chen YB
    Haematologica; 2017 Apr; 102(4):719-727. PubMed ID: 28034990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase I Study of the Aurora A Kinase Inhibitor Alisertib in Combination With Irinotecan and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma: A NANT (New Approaches to Neuroblastoma Therapy) Trial.
    DuBois SG; Marachelian A; Fox E; Kudgus RA; Reid JM; Groshen S; Malvar J; Bagatell R; Wagner L; Maris JM; Hawkins R; Courtier J; Lai H; Goodarzian F; Shimada H; Czarnecki S; Tsao-Wei D; Matthay KK; Mosse YP
    J Clin Oncol; 2016 Apr; 34(12):1368-75. PubMed ID: 26884555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies.
    Zhou X; Pant S; Nemunaitis J; Craig Lockhart A; Falchook G; Bauer TM; Patel M; Sarantopoulos J; Bargfrede M; Muehler A; Rangachari L; Zhang B; Venkatakrishnan K
    Invest New Drugs; 2018 Apr; 36(2):248-258. PubMed ID: 28852909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Food on the Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib (MLN8237) in Patients with Advanced Solid Tumors.
    Falchook GS; Zhou X; Venkatakrishnan K; Kurzrock R; Mahalingam D; Goldman JW; Jung J; Ullmann CD; Milch C; Rosen LS; Sarantopoulos J
    Drugs R D; 2016 Mar; 16(1):45-52. PubMed ID: 26689566
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population Pharmacokinetics and Exposure-Safety Relationships of Alisertib in Children and Adolescents With Advanced Malignancies.
    Zhou X; Mould DR; Yuan Y; Fox E; Greengard E; Faller DV; Venkatakrishnan K
    J Clin Pharmacol; 2022 Feb; 62(2):206-219. PubMed ID: 34435684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 1 study of alisertib (MLN8237) and weekly irinotecan in adults with advanced solid tumors.
    Semrad TJ; Kim EJ; Gong IY; Li T; Christensen S; Arora M; Riess JW; Gandara DR; Kelly K
    Cancer Chemother Pharmacol; 2021 Aug; 88(2):335-341. PubMed ID: 33993383
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase 2 study of alisertib (MLN8237) in recurrent or persistent uterine leiomyosarcoma: An NRG Oncology/Gynecologic Oncology Group study 0231D.
    Hyman DM; Sill MW; Lankes HA; Piekarz R; Shahin MS; Ridgway MR; Backes F; Tenney ME; Mathews CA; Hoffman JS; Aghajanian C; Hensley ML
    Gynecol Oncol; 2017 Jan; 144(1):96-100. PubMed ID: 28094040
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacokinetics of the Investigational Aurora A Kinase Inhibitor Alisertib in Adult Patients With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Dysfunction.
    Zhou X; Lockhart AC; Fu S; Nemunaitis J; Sarantopoulos J; Muehler A; Rangachari L; Bargfrede M; Venkatakrishnan K
    J Clin Pharmacol; 2019 Sep; 59(9):1204-1215. PubMed ID: 30985952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aurora A Functional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor.
    Niu H; Shin H; Gao F; Zhang J; Bahamon B; Danaee H; Melichar B; Schilder RJ; Coleman RL; Falchook G; Adenis A; Behbakht K; DeMichele A; Dees EC; Perez K; Matulonis U; Sawrycki P; Huebner D; Ecsedy J
    EBioMedicine; 2017 Nov; 25():50-57. PubMed ID: 29122619
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.